Literature DB >> 12505030

Mutation rate and the efficacy of antimicrobial drug treatment.

Philip J Gerrish1, J Gerardo García-Lerma.   

Abstract

Despite rapid progress in drug development, microbial infections in general are becoming increasingly difficult to treat as a result of the emergence of drug-resistant strains. In some cases, such as HIV-1, the early goal of eradicating infections with antimicrobial drugs is, for now, being replaced with the more pragmatic goal of controlling infections over long periods of time through a succession of transiently effective treatments. Because treatment efficacy is often incomplete, studying the degree of treatment efficacy has great relevance to clinical disease management. We derived a model describing the association between the mutation rate of the pathogen and the degree of treatment efficacy. We found that drug treatment is most effective when the mutation rate of the pathogen is either very low or, perhaps counterintuitively, very high. We discuss this finding in the light of a promising new treatment strategy for RNA viruses that combines antiviral compounds with a mutagen.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12505030     DOI: 10.1016/s1473-3099(03)00485-7

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  12 in total

1.  Suppression of viral infectivity through lethal defection.

Authors:  Ana Grande-Pérez; Ester Lázaro; Pedro Lowenstein; Esteban Domingo; Susanna C Manrubia
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-14       Impact factor: 11.205

2.  Compensation of fitness costs and reversibility of antibiotic resistance mutations.

Authors:  Pia Schulz zur Wiesch; Jan Engelstädter; Sebastian Bonhoeffer
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

3.  Mutation of HIV-1 genomes in a clinical population treated with the mutagenic nucleoside KP1461.

Authors:  James I Mullins; Laura Heath; James P Hughes; Jessica Kicha; Sheila Styrchak; Kim G Wong; Ushnal Rao; Alexis Hansen; Kevin S Harris; Jean-Pierre Laurent; Deyu Li; Jeffrey H Simpson; John M Essigmann; Lawrence A Loeb; Jeffrey Parkins
Journal:  PLoS One       Date:  2011-01-14       Impact factor: 3.240

4.  Lethal mutagenesis and evolutionary epidemiology.

Authors:  Guillaume Martin; Sylvain Gandon
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2010-06-27       Impact factor: 6.237

5.  Deciphering Evolutionary Mechanisms Between Mutualistic and Pathogenic Symbioses.

Authors:  M K Nishiguchi; A M Hirsch; R Devinney; G Vedantam; M A Riley; L M Mansky
Journal:  Vie Milieu       Date:  2008       Impact factor: 0.236

Review 6.  Quasispecies theory and the behavior of RNA viruses.

Authors:  Adam S Lauring; Raul Andino
Journal:  PLoS Pathog       Date:  2010-07-22       Impact factor: 6.823

7.  Template properties of mutagenic cytosine analogues in reverse transcription.

Authors:  Tetsuya Suzuki; Kei Moriyama; Chie Otsuka; David Loakes; Kazuo Negishi
Journal:  Nucleic Acids Res       Date:  2006-11-27       Impact factor: 16.971

8.  Cell tropism predicts long-term nucleotide substitution rates of mammalian RNA viruses.

Authors:  Allison L Hicks; Siobain Duffy
Journal:  PLoS Pathog       Date:  2014-01-09       Impact factor: 6.823

9.  The diversification of begomovirus populations is predominantly driven by mutational dynamics.

Authors:  Alison T M Lima; José C F Silva; Fábio N Silva; Gloria P Castillo-Urquiza; Fabyano F Silva; Yee M Seah; Eduardo S G Mizubuti; Siobain Duffy; F Murilo Zerbini
Journal:  Virus Evol       Date:  2017-03-02

10.  Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infections.

Authors:  Celia Perales; Rubén Agudo; Hector Tejero; Susanna C Manrubia; Esteban Domingo
Journal:  PLoS Pathog       Date:  2009-11-13       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.